BOSTON, June 12 /PRNewswire-FirstCall/ -- PAREXEL International Corporation , a leading global bio/pharmaceutical services organization, is making patient recruitment and retention strategy, planning and execution more effective for clinical trial sponsors with an expanded offering that includes an expert recruitment team supported by new technology that it believes substantially improves patient recruitment performance.
In order to streamline and analyze all the disparate factors across the organization that can impact Last Patient In (LPI) recruitment goals, PAREXEL has organized a unique, global Start-up and Accelerated Recruitment Team (START). START relies upon a new suite of proprietary technologies and data assets to more accurately plan for recruitment milestones. The new Scenario Planning and Recruitment Calculator (SPARC(TM)) integrates data from across the organization to help drug sponsors avoid costly delays caused by slow recruitment or poor patient retention. With these data, START is also able to implement pre-planned contingencies based upon ongoing information, helping to avoid potential problems.
According to Mark A. Goldberg, M.D., President of Clinical Research Services and Perceptive Informatics, PAREXEL, “Successfully achieving LPI milestones requires using all of the levers that PAREXEL, as a global CRO, has at its fingertips. Our expanded patient recruitment services let sponsors harness experience from some of the industry’s strongest recruitment specialists and the power of a solid technology platform that streamlines the entire process.”
Another critical aspect of PAREXEL’s expanded recruitment capabilities is an enhanced investigator database that is used in conjunction with the SPARC to plan trials and identify high potential investigators.
“Investigator databases are often limited to lists of contact information, trial participation and therapeutic specialty. PAREXEL enhances these basic data with comprehensive information on patient enrollment success and other historic recruiting performance indicators. We believe we can provide sponsors all the facts they need to select the best sites for their trial,” commented Joshua Schultz, Vice President, Patient Recruitment, Clinical Research Services, PAREXEL.
For more information about START visit www.PAREXEL.com or visit Booth #724 at the DIA’s 43rd Annual Meeting.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 55 locations throughout 43 countries around the world, and has over 6,315 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes”, “anticipates”, “plans”, “expects”, “intends”, “appears”, “estimates”, “projects”, “targets” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2007 as filed with the SEC on May 9, 2007, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.
Contacts: Karen Wills, Vice President, Corporate Marketing PAREXEL International Tel: +781-434-5301 Email: Karen.Wills@PAREXEL.com Rebecca Passo SHIFT Communications Tel: +617-779-1817 Email: rpasso@shiftcomm.com
PAREXEL International Corporation
CONTACT: Karen Wills, Vice President, Corporate Marketing, of PAREXELInternational, +1-781-434-5301, Karen.Wills@PAREXEL.com, or Rebecca Passoof SHIFT Communications, +1-617-779-1817, or rpasso@shiftcomm.com
Web site: http://www.parexel.com/
